ArticlePsychopharmacology2014
CB2 receptor agonism reverses MK-801-induced disruptions of prepulse inhibition in mice.
Article in Psychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- Clinical and cognitive outcomes in first-episode psychosis: focus on the interplay between cannabis use and genetic variability in endocannabinoid receptors.Frontiers in psychology · 2024Article
- Adolescent exposure to the Spice/K2 cannabinoid JWH-018 impairs sensorimotor gating and alters cortical perineuronal nets in a sex-dependent manner.Translational psychiatry · 2023Article
- Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders.International journal of molecular sciences · 2022Review
- New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders.International journal of molecular sciences · 2022Review
- Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders.Frontiers in psychiatry · 2022Review
- CB2 cannabinoid receptor expression is increased in 129S1/SvImJ mice: behavioral consequences.Frontiers in pharmacology · 2022Article
- Cannabinoid type-2 receptors: An emerging target for regulating schizophrenia-relevant brain circuits.Frontiers in neuroscience · 2022Review
- Molecular Findings Guiding the Modulation of the Endocannabinoid System as a Potential Target to Treat Schizophrenia.Advances in experimental medicine and biology · 2022Article
- Cognitive behavioral markers of neurodevelopmental trajectories in rodents.Translational psychiatry · 2021Article
- Are CB2 Receptors a New Target for Schizophrenia Treatment?Frontiers in psychiatry · 2020Review
- Endocannabinoid System Components as Potential Biomarkers in Psychiatry.Frontiers in psychiatry · 2020Review
- Effects of Fatty Acid Amide Hydrolase Inhibitors Acute Administration on the Positive and Cognitive Symptoms of Schizophrenia in Mice.Molecular neurobiology · 2019Article
- GLYX-13 Ameliorates Schizophrenia-Like Phenotype Induced by MK-801 in Mice: Role of Hippocampal NR2B and DISC1.Frontiers in molecular neuroscience · 2018Article
- The Impact of CB2 Receptor Ligands on the MK-801-Induced Hyperactivity in Mice.Neurotoxicity research · 2017Article
- Interaction between NMDA and CB2 function in the dorsal hippocampus on memory consolidation impairment: an isobologram analysis.Psychopharmacology · 2017Article
- An Introduction to the Endogenous Cannabinoid System.Biological psychiatry · 2016Review
- Microglial Cells as a Link between Cannabinoids and the Immune Hypothesis of Psychiatric Disorders.Frontiers in neurology · 2016Review
- Subchronic pharmacological and chronic genetic NMDA receptor hypofunction differentially regulate the Akt signaling pathway and Arc expression in juvenile and adult mice.Schizophrenia research · 2015Article
- Sensorimotor gating impairments induced by MK-801 treatment may be reduced by tolerance effect and by familiarization in monkeys.Frontiers in pharmacology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleWhilst cannabinoid CB2 receptors were thought to exist predominantly in immune cells in the periphery, the recent discovery of CB2 receptors in the brain has led to an increased interest in the role of these central CB2 receptors. Several studies have reported an association with CB2 receptors and schizophrenia. Sensorimotor gating deficits occur in schizophrenia patients and can be induced in animals using psychotomimetic drugs such as N-methyl-D-aspartate (NMDA) receptor antagonists.
objectivesThe aim of this study was to investigate the effect of CB2 ligands on sensorimotor gating, either alone, or on sensorimotor gating deficits induced by the NMDA receptor antagonist MK-801 in mice.
methodThe effects of CB2 receptor ligands on prepulse inhibition (PPI), an operational measure of sensorimotor gating, alone or when administrated in combination with MK-801, in Balb-C mice were evaluated.
resultsThe CB2 receptor agonist JWH015 had no significant effect on PPI alone but reversed disruptions in PPI induced by MK-801. This effect was blocked by co-administration of the CB2 receptor antagonist AM630, but not by co-administration of the CB1 receptor antagonist AM251, indicating a CB2-mediated effect. The mixed CB1/CB2 receptor agonist JWH203 was partially able to reverse MK-801-induced PPI disruptions. Neither the CB2 receptor antagonist AM630 nor the CB1 receptor antagonist AM251 had any significant effect alone or on MK-801-induced disruptions in PPI.
conclusionsCB2 receptor agonism reversed MK-801 disruptions in sensorimotor gating deficits in mice, indicating that CB2 agonism may have a protective effect against aspects of drug-induced psychosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.